Skip to content

Fecal Microbiota Transplantation for Liver Failure

The Clinical Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Acute-on-chronic Liver Failure

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05170971
Enrollment
60
Registered
2021-12-28
Start date
2021-05-01
Completion date
2026-12-31
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure

Keywords

fecal microbiota transplantation, gut-liver axis, liver failure

Brief summary

To investigate the safety, adverse reactions and therapeutic effects of fecal microbiota transplantation on patients with liver failure;to investigate the effect of fecal microbiota transplantation on the intestinal microecology and gut-liver axis immune system of liver failure, and further optimization of fecal microbiota transplantation technology.

Interventions

OTHERfecal microbiota transplantation

The fecal bacteria were transplanted once every 5 days for a total of 4 times

Sponsors

Ningbo Medical Center Lihuili Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients willing to sign informed consent * Patients aged 18-65 * According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL ≥ 10 × ULN or the daily rise ≥ 17.1 μ mol / L; there was bleeding, PTA ≤ 40% (or INR ≥ 1.5)

Exclusion criteria

* Patients with severe heart failure, COPD, cerebrovascular accident, nephrotic syndrome, etc; * Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc * Patients with liver cancer, lung cancer, lymphoma and other malignant tumors * Patients taking anticoagulants, mental diseases and immune diseases for a long time * Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
gut microbiota changeFecal samples were collected 1 week before faecal bacteria transplantation, and change from at 5 day, 10 day, 15 day, 20 day, 4 and 8 weeks after faecal bacteria transplantation, respectivelyGene sequencing and metabonomics analysis of fecal flora.
Observe the clinical manifestations, safety and adverse reactions of the patientsThese indicators were collected 1 week before faecal bacteria transplantation, and change from at 5 day, 10 day, 15 day, 20 day, 4 and 8 weeks after faecal bacteria transplantation, respectivelySafety and adverse events were assessed including fever, diarrhea and elevated inflammatory markers (such as C-reactive protein and procalcitonin) before and after faecal bacteria transplantation.
Liver function changeBlood samples were collected 1 week before faecal bacteria transplantation, and followed up at 5 day, 10 day, 15 day, 20 day, 4 and 8 weeks after faecal bacteria transplantation, respectivelyThe investigators need to monitor the changes in liver and kidney function before and after faecal bacteria transplantation,such as ALT、AST、GGT 、TBIL(The units of these indices are U/L).
Coagulation function changeBlood samples were collected 1 week before faecal bacteria transplantation, and followed up at 5 day, 10 day, 15 day, 20 day, 4 and 8 weeks after faecal bacteria transplantation, respectivelyProthrombin activity are one of the indexes to evaluate the degree of liver failure in patients.The units of this indices is %.
Model for end-stage liver disease score changeModel for end-stage liver disease score were obtained separately in 1 week before faecal bacteria transplantation, and to access once again at 5 day, 10 day, 15 day, 20 day, 4 and 8 weeks after faecal bacteria transplantation, respectivelyThe model for end-stage liver disease (MELD) score is a prospectively developed and validated scale for the severity of end-stage liver disease.The higher the MELD score, the more severe the liver disease and the greater the risk of death. The fatality rate of patients with MELD between 20 and 30 was more than 30%, that of patients with MELD between 30 and 40 was more than 50%, and that of patients with MELD \>40 was more than 70%.
proinflammatory cytokine changeBlood samples were collected 1 week before faecal bacteria transplantation, and followed up at 5 day, 10 day, 15 day, 20 day, 4 and 8 weeks after faecal bacteria transplantation, respectivelyIL-17,IL-6,TNF-α, TGF-β, IFN-γ and other cytokines were detected by ELISA(The units of these indices are pg/mL).

Countries

China

Contacts

Primary Contactlanman Xu
13587646315@163.com+86 13587646315

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026